Skip to main content

Advertisement

Table 4 Summary of the reported cases of clinical infections by Streptococcus gallolyticus subsp. pasteurianus

From: Microbiological and clinical characteristics of Streptococcus gallolyticus subsp. pasteurianus infection in China

  present study 1 [4] 2 [11] 3[14] 4 [20] 5[21]
Number 45 20 patients (22 isolates were recovered) 126 24 13 2
Study period 2011–2017 May 2010-Jan 2012 2000–2012 January 2003 and January 2010 2004–2010 1988–2014
Country/area China Italy Taiwan Spain Israel Spain
Demographic characteristics
 Gender (Male/female) 17/28 7/13 79/47 NA 7/6 1/1
 Age (mean ± SD or median and IQD, years) 67 ± 22 72 ± 13 70(55,78) NA 60 ± 33 89 and 62
  Age > 65 years 19(42.2%) 15 76(60%) NA NA 1(50%)
  Pregnant women 11(24.4%) 0 NA NA 2(15%) 0
  Neonates(< 3 months of age) 1(2.2%) 0 NA NA 2(15%) 0
  Paediatric patients (< 18 years) 1(2.2%) 0 5(4%) NA NA NA
Infection types/source Bacteremia (17), urine (16), bile (1), ascitic fluid (1), abdominal puncture fluid (1), peripancreatic drainage (1), peritoneal fluid (1), CSF(1) and fetal membrane/placenta (9) UTI(10), bacteremia(2), limb ulcer (1), bile(3) Bacteremia(126) Bacteremia(24) Bacteremia(13) Spondylodiscitis/ paravertebral abscess (1), pubicsymphysitis and UTI(1)
Underlying diseases
 Diabetes 10(22.2%) 8(40%) 43(34%) 2(8.3%) 2(15%) 1(50%)
 Chronic renal failure NA 1(5%) 22(17%) 1(4.2%) 3(23%) NA
 Liver disease NA 4(20%) 53(42%) NA 4(31%) NA
 Malignancy (past or active) 4(8.9%) 6(30%) 68(54%) 9(37.5%, colonic adenoma (4); bladder cancer(1); prostate cancer(1); pulmonary cancer(1); mucosa-associated lymphoid tissue lymphoma (1); leukemia(1)) 3(23%) Adenoma(1); prostate cancer(1)
 Gastrointestinal tract tumors 4(8.9%) 4(20%) 51(40%, including colon/rectum, stomach, pancreas, liver, bile duct). 4(16.7%) 4(31%) 1(50%)
 Biliary pathology 1(2.2%) 4(20%) 9(7%, biliary tract stone) 5(20.8%) 2(15%) NA
 Bacteriuria 16(35.6%) 14(70%)(50% UTI); 2(2%) 0 NA 1(50%)
 Endocarditis 1(2.2%) 2(10%) 17(13%) 6(25%) 3(23%) 1(50%)
 Identification methods BD Phoenix 100, 16S rRNA/gyrB sequencing Phoenix100, 16S rDNA sequencing, MALDI Biotyper Bruker and Vitek MS Vitek automated system; 16S rRNA and sodA genes and PCR-RFLP assays of groESL gene API 20 Strep system, semiautomated Wider system, 16S rRNA and sodA PCR, Bruker Biotyper MALDI-TOF MS PCR-RFLP/Vitek 2 API 20 Strep system/ Vitek 2, 16S rRNA/sodA sequencing
Antibiotic susceptibility rate (median, μg/mL)(susceptibility rate(%))
 penicillin 0.125(100) NA(100) 0.06(100) NA (NA) 0.06(100) NA (NA)
 cefatriaxone < 0.5(100) NA(100% to cefotaxime) 0.12(100) NA (NA) 0.09(100) NA (NA)
 erythromycin > 4(11.1%, erm(B)/erm(A), erm(B)/mef(A/E), and erm(B)/erm(T) were detected in 7, 4, and 3 isolates, respectively). NA(68.2%, all resistant isolates belonged to the cMLSB phenotype, carried erm(B)). 32(37%) 0.5(62.5%) NA (NA) NA (NA)
 clindamycin > 4(11.1%) NA(68.2%) 0.06(39%) 0.5(75%) NA (NA) NA (NA)
 levofloxacin 2(73.3%) NA (NA) 2(82%) 0.5(91.7%) NA (NA) NA (NA)
 vancomycin ≤0.25 NA (NA) 0.5(100%) NA (NA) NA (NA) NA (NA)
 tetracycline (μg/mL) > 8((4.4%), 39 strains carried tet(L), 27 tet(O), and 7 tet(M), alone or combined, respectively.) NA(31.8%, the resistant isolates carried tet(O)(11) and tet(M)(4). NA (NA) NA (NA) NA (NA) NA (NA)
  1. NA Not available, CSF Cerebrospinal fluid, UTI urinary tract infection; Number in parentheses represents strains, and no number signified only one strain was detected